Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension
Respira Therapeutics Enters into Agreement with Gossamer Bio Granting Gossamer Option to Acquire Respira from Samsara BioCapital
Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On?Demand Vardenafil for Pulmonary Hypertension
Drilling Resumes on Berrigan Zinc, Gold, Silver Property under Option from Chibougamau Independent Mines
Angkor Resources Undertakes IP Survey Over Copper/Iron Skarn Adjacent to Canada Wall Copper Porphyry Target, Andong Meas License, Cambodia
American Uranium Advances Wyoming ISR Development with Resource Growth and Confidence Upgrade at Lo Herma
